AR041243A1 - Vacuna para ostertagia - Google Patents
Vacuna para ostertagiaInfo
- Publication number
- AR041243A1 AR041243A1 ARP030103307A ARP030103307A AR041243A1 AR 041243 A1 AR041243 A1 AR 041243A1 AR P030103307 A ARP030103307 A AR P030103307A AR P030103307 A ARP030103307 A AR P030103307A AR 041243 A1 AR041243 A1 AR 041243A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- proteins
- parts
- refers
- acid sequences
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 150000007523 nucleic acids Chemical group 0.000 abstract 11
- 108090000623 proteins and genes Proteins 0.000 abstract 11
- 102000004169 proteins and genes Human genes 0.000 abstract 11
- 230000002163 immunogen Effects 0.000 abstract 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 4
- 241000243794 Ostertagia ostertagi Species 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 108020004414 DNA Proteins 0.000 abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a secuencias de ácidos nucleicos que codifican a proteínas de Ostertagia ostertagi y a partes de tales secuencias de ácidos nucleicos que codifican a un fragmento inmunogénico de tales proteínas, y a fragmentos de ADN,moléculas de ADN recombinantes, portadores recombinantes vivos y células huésped que comprenden a tales secuencias de ácidos nucleicos o tales partes de las mismas. La presente también se refiere a proteínas de Ostertagia ostertagi y a partesinmunogénicas de las mismas codificadas por tales secuencias. Además, la presente se refiere a vacunas que comprenden tales secuencias de ácidos nucleicos y a partes de las mismas, fragmentos de ADN, moléculas de ADN recombinante, portadoresrecombinantes vivos y células huésped que comprenden a tales secuencias de ácidos nucleicos o tales partes de las mismas, proteínas o partes inmunogénicas de las mismas y anticuerpos contra tales proteínas o partes inmunogénicas de las mismas.Además, la presente se refiere al uso de dichas proteínas en vacunas y para la elaboración de vacunas. Además, la presente se refiere al uso de dichas secuencias de ácidos nucleicos, proteínas o anticuerpos para propósitos de diagnóstico o devacunación. Finalmente, la presente se refiere a kits de diagnóstico que comprenden a tales ácidos nucleicos, proteínas o anticuerpos contra tales proteínas. Reivindicación 1: Secuencia de ácidos nucleicos que codifica a una proteína de Ostertagiaostertagi o una parte de dicha secuencia de ácidos nucleicos que codifica a un fragmento inmunogénico de dicha proteína, teniendo secuencia de ácidos nucleicos o dicha parte de la misma por lo menos 85%, preferentemente 90, más preferentemente 95%de homología con la secuencia de ácidos nucleicos del gen de la proteína de Ostertagia ostertagi como se ilustra en la SEQ ID NO: 7.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/243,319 US20040052817A1 (en) | 2002-09-13 | 2002-09-13 | Ostertagia vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041243A1 true AR041243A1 (es) | 2005-05-11 |
Family
ID=31991608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103307A AR041243A1 (es) | 2002-09-13 | 2003-09-12 | Vacuna para ostertagia |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20040052817A1 (es) |
| EP (1) | EP1539820B1 (es) |
| AR (1) | AR041243A1 (es) |
| AT (1) | ATE392435T1 (es) |
| AU (1) | AU2003270190B2 (es) |
| BR (2) | BRPI0314258B1 (es) |
| CA (1) | CA2498249C (es) |
| DE (1) | DE60320425T2 (es) |
| ES (1) | ES2304526T3 (es) |
| NZ (1) | NZ542733A (es) |
| WO (1) | WO2004024769A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1546333A4 (en) * | 2002-09-13 | 2005-12-21 | Ovita Ltd | INHIBITOR OF ASPARTYL PROTEASE IN PLACE OF NEMATODE ALLERGENE |
| US20040052817A1 (en) * | 2002-09-13 | 2004-03-18 | Peter Geldhof | Ostertagia vaccine |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB894603A (en) * | 1959-09-02 | 1962-04-26 | Allen & Hanburys Ltd | Improvements in or relating to vaccines |
| EP0721466A1 (en) | 1993-09-28 | 1996-07-17 | The University Of Melbourne | Protective antigens against parasites |
| US5753787A (en) * | 1995-04-10 | 1998-05-19 | Yale University | Nucleic acids encoding ancylostoma secreted protein |
| US5759782A (en) * | 1995-06-07 | 1998-06-02 | The United States Of America | Cellular apoptosis susceptibility protein (CSP) and antisense CSP |
| US6017757A (en) * | 1997-02-20 | 2000-01-25 | Mississippi State University | Isolated viable nematode intestinal cells |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| US20040052817A1 (en) | 2002-09-13 | 2004-03-18 | Peter Geldhof | Ostertagia vaccine |
-
2002
- 2002-09-13 US US10/243,319 patent/US20040052817A1/en not_active Abandoned
-
2003
- 2003-09-11 BR BRPI0314258-2A patent/BRPI0314258B1/pt unknown
- 2003-09-11 AU AU2003270190A patent/AU2003270190B2/en not_active Expired
- 2003-09-11 ES ES03750540T patent/ES2304526T3/es not_active Expired - Lifetime
- 2003-09-11 EP EP03750540A patent/EP1539820B1/en not_active Expired - Lifetime
- 2003-09-11 NZ NZ542733A patent/NZ542733A/en not_active IP Right Cessation
- 2003-09-11 WO PCT/EP2003/010189 patent/WO2004024769A2/en active IP Right Grant
- 2003-09-11 AT AT03750540T patent/ATE392435T1/de not_active IP Right Cessation
- 2003-09-11 CA CA2498249A patent/CA2498249C/en not_active Expired - Lifetime
- 2003-09-11 DE DE60320425T patent/DE60320425T2/de not_active Expired - Lifetime
- 2003-09-11 US US10/527,771 patent/US7264812B2/en not_active Expired - Lifetime
- 2003-09-11 BR BR0314258-2A patent/BR0314258A/pt active IP Right Grant
- 2003-09-12 AR ARP030103307A patent/AR041243A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 US US11/832,836 patent/US7718179B2/en not_active Expired - Lifetime
-
2010
- 2010-04-16 US US12/761,923 patent/US8227584B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7718179B2 (en) | 2010-05-18 |
| US20050271683A1 (en) | 2005-12-08 |
| WO2004024769A3 (en) | 2004-06-03 |
| DE60320425T2 (de) | 2008-07-31 |
| CA2498249A1 (en) | 2004-03-25 |
| CA2498249C (en) | 2016-09-06 |
| BR0314258A (pt) | 2005-07-26 |
| ATE392435T1 (de) | 2008-05-15 |
| AU2003270190A1 (en) | 2004-04-30 |
| US20090028892A1 (en) | 2009-01-29 |
| US8227584B2 (en) | 2012-07-24 |
| EP1539820B1 (en) | 2008-04-16 |
| US20100209446A1 (en) | 2010-08-19 |
| US7264812B2 (en) | 2007-09-04 |
| EP1539820A2 (en) | 2005-06-15 |
| DE60320425D1 (de) | 2008-05-29 |
| NZ542733A (en) | 2007-06-29 |
| WO2004024769A2 (en) | 2004-03-25 |
| BRPI0314258B1 (pt) | 2019-07-09 |
| US20040052817A1 (en) | 2004-03-18 |
| ES2304526T3 (es) | 2008-10-16 |
| AU2003270190B2 (en) | 2008-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545886T3 (es) | Inmunoterapia dirigida a patógenos intracelulares | |
| DE69739515D1 (de) | Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. | |
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| EA201071323A1 (ru) | Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения | |
| MXPA06008217A (es) | Vacunas con subunidad de lawsonia intracellularis. | |
| RU2009123028A (ru) | F-белок респираторно-синцитиального вируса (rsv) и его применение | |
| HUP0105379A2 (hu) | Lawsonia intracellularis elleni oltóanyag | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| NZ598605A (en) | Vaccine against african horse sickness virus | |
| AR015252A1 (es) | Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo | |
| AR036793A1 (es) | Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante | |
| WO2003095480A3 (en) | Brachyspira hyodysenteriae vaccine | |
| ATE450545T1 (de) | Impfstoff mit lawsonia intracellularis- untereinheit | |
| AR041243A1 (es) | Vacuna para ostertagia | |
| ZA200602107B (en) | Piroplasmid vaccine | |
| AR040830A1 (es) | Vacuna para combatir la infeccion que produce la mastitis | |
| NO20081541L (no) | Ny sjo-lus vaksine | |
| PL1962889T3 (pl) | Immunogenny polipeptyd złożony z optymalizowanych kryptycznych peptydów wyprowadzonych z antygenu nowotworu oraz jego zastosowania | |
| AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
| WO2004007726A3 (en) | Brachyspira hyodysenteriae vaccine | |
| CU23245A1 (es) | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS | |
| BRPI0412419A (pt) | proteìna de babésia, ácido nucleico, fragmento de cdna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, vacina, método para a preparação de uma vacina, uso de uma proteìna ou um fragmento imunogênico de referida proteìna, e, testes diagnósticos para a detecção de um ácido nucleico associado com, para a detecção de anticorpos contra, e para a detecção de material antigênico de um organismo da famìlia babesiidae | |
| DE50106199D1 (de) | Regulatorische sequenz zur spezifischen expression in dendritischen zellen und deren anwendungen | |
| BRPI0417440A (pt) | ácido nucleico, fragmento e molécula de dna, veìculo recombinante vivo, célula hospedeira, proteìna de lawsonia intracellularis, vacina para combater as infecções com lawsonia intracelularis, método para a preparação de uma vacina, e, testes de diagnóstico para aldetecção de anticorpos contra lawsonia intracellularis e material antigênico de lawsonia intracellularis | |
| HUP0200832A2 (hu) | Babesia canis oltóanyag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |